Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Liabilities and Shareholders Equity (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 3.95% year-over-year to $93.0 million, compared with a TTM value of $398.4 million through Dec 2025, down 2.26%, and an annual FY2025 reading of $93.0 million, down 3.95% over the prior year.
  • Liabilities and Shareholders Equity was $93.0 million for Q4 2025 at aTYR PHARMA, down from $106.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $136.8 million in Q1 2023 and bottomed at $49.0 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $102.9 million, with a median of $103.2 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity surged 198.34% in 2021, then decreased 26.75% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $115.5 million in 2021, then fell by 17.09% to $95.8 million in 2022, then increased by 25.96% to $120.7 million in 2023, then dropped by 19.75% to $96.8 million in 2024, then fell by 3.95% to $93.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ATYR at $93.0 million in Q4 2025, $106.7 million in Q3 2025, and $101.5 million in Q2 2025.